GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (FRA:JC4) » Definitions » 10-Year Sharpe Ratio

Universal Ibogaine (FRA:JC4) 10-Year Sharpe Ratio : N/A (As of Jul. 10, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Universal Ibogaine 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2025-07-10), Universal Ibogaine's 10-Year Sharpe Ratio is Not available.


Competitive Comparison of Universal Ibogaine's 10-Year Sharpe Ratio

For the Biotechnology subindustry, Universal Ibogaine's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's 10-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's 10-Year Sharpe Ratio falls into.


;
;

Universal Ibogaine 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.


Universal Ibogaine  (FRA:JC4) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Universal Ibogaine 10-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's 10-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine Business Description

Traded in Other Exchanges
Address
C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.

Universal Ibogaine Headlines

No Headlines